The Fourth affiliated Hospital, Zhejiang University School of Medicine, Yiwu 322000, China.
The Second affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 31000, China.
Biochim Biophys Acta Rev Cancer. 2023 Sep;1878(5):188943. doi: 10.1016/j.bbcan.2023.188943. Epub 2023 Jun 22.
Pancreatic ductal adenocarcinoma (PDAC) is one of the lethal cancers in the world and its 5-year survival rate is <10%. Due to the unique TME and dense tissue structure, its curative efficacy is far from satisfactory，the immunotherapy is even more invalid. According to the recent studies, the gut and tumor microbiota have been proved to play a key role in the development, progression and prognosis of PDAC. Based on the differences of microbiome composition observed in PDAC patients and normal pancreas, many researches have been made focusing on the latent communication between gut and intra-tumor microbiota and PDAC. In this review, we will demonstrate the potential mechanism of the oncogenic effects of GM and IM and their crucial effects on modulating the TME. Besides, we focus on their interaction with chemotherapeutic and immunotherapeutic drugs and inducing the drug resistance, thus enlightening the promising role to be used to monitor the occurrence of PDAC, accurately modulate the immune environment to promote the therapeutic efficacy and predict the prognosis.
胰腺导管腺癌 (PDAC) 是世界上致命的癌症之一，其 5 年生存率<10%。由于独特的 TME 和致密的组织结构，其疗效远不能令人满意，免疫疗法甚至更无效。根据最近的研究，肠道和肿瘤微生物群已被证明在 PDAC 的发展、进展和预后中发挥关键作用。基于在 PDAC 患者和正常胰腺中观察到的微生物组组成的差异，许多研究集中在肠道和肿瘤内微生物群与 PDAC 之间的潜在通信上。在这篇综述中，我们将展示 GM 和 IM 的致癌作用的潜在机制及其对调节 TME 的关键作用。此外，我们还关注它们与化疗和免疫治疗药物的相互作用以及诱导耐药性，从而为监测 PDAC 的发生、准确调节免疫环境以促进治疗效果和预测预后提供有希望的作用。
